nach oben

International Journal of Clinical Oncology

Erschienen in:

01.04.2019 | Original Article

To what extent does the EQ-5D-3L correlate with the FACT-H&N of patients with oral cancer during the perioperative period?

verfasst von: Takayuki Aoki, Yoshihide Ota, Masashi Sasaki, Ken-ichi Aoyama, Takeshi Akiba, Yukari Shirasugi, Mariko Naito, Takeru Shiroiwa

Erschienen in: International Journal of Clinical Oncology | Ausgabe 4/2019

Einloggen, um Zugang zu erhalten

Abstract

Background

The EuroQol 5-dimension scale (EQ-5D) is one of the most frequently used preference-based quality of life (QOL) measures for health technology assessment. The 3-level version of the EQ-5D comprises a descriptive system (the EQ-5D-3L) and a visual analog scale (EQ-VAS). It remains unclear whether this five-item scale correlates with the QOL of patients with oral cancer during the perioperative period. We sought to clarify this point in the present study.

Methods

Participants were 84 patients with oral malignancies who underwent radical treatment and completed the EQ-5D-3L and Functional Assessment of Cancer Therapy-Head and Neck (FACT-H&N) at regular intervals over 3 months after treatment. We analyzed the correlations between the EQ-5D-3L, EQ-VAS, and FACT-H&N, and conducted multiple regression analyses to examine how the FACT-H&N subscales relate to the EQ-5D-3L and EQ-VAS. We also investigated whether the EQ-5D-3L shows ceiling effects.

Results

The EQ-5D-3L and EQ-VAS were strongly correlated with the FACT-H&N (r_s = 0.621 and 0.638, respectively; P < 0.01). Furthermore, the EQ-5D-3L was significantly related with all FACT-H&N subscales except for social/family well-being. Particularly, the physical well-being subscale had the strongest relationship with the EQ-5D-3L. The FACT H&N and EQ-5D-3L showed similar changes over time. The EQ-5D-3L did not have a ceiling effect statistically.

Conclusions

Our results indicate that actual physical performance might be most important for cost–utility analysis, whereas the assessment of familial feelings or friendship seems less important. However, the EQ-5D-3L appears to generally correlate with the FACT-H&N of patients with oral cancer during the perioperative period. Therefore, it is reasonable to assess the cost performance of oral cancer treatment using the EQ-5D-3L in Japan.

Drummond MF, Sculpher MJ, Claxton K et al (2015) Methods for the economic evaluation of health care programmes, 4th edn. Oxford University Press, Oxford

Longworth L, Yang Y, Young T et al (2014) Use of generic and condition-specific measures of health-related quality of life in NICE decision-making: a systematic review, statistical modelling and survey. Health Technol Assess 18:1–224. https://doi.org/10.3310/hta18090 CrossRefPubMedPubMedCentral

Tosh JC, Longworth LJ, George E (2011) Utility values in national institute for health and clinical excellence (NICE) technology appraisals. Value Health 14:102–109. https://doi.org/10.1016/j.jval.2010.10.015 CrossRefPubMed

List MA, D’Antonio LL, Cella DF, et al (1996) The performance status scale for head and neck cancer patients and the functional assessment of cancer therapy-head and Neck Scale. A study of utility and validity. Cancer 77:2294–2301. https://doi.org/10.1002/(sici)1097-0142(19960601)77:11%3C2294::aid-cncr17%3E3.3.co;2-t.CrossRefPubMed

Bjordal K, Kaasa S (1992) Psychometric validation of the EORTC Core Quality of Life Questionnaire, 30-item version and a diagnosis-specific module for head and neck cancer patients. Acta Oncol 31:311–321CrossRefPubMed

EuroQol Group (1990) EuroQol–a new facility for the measurement of health-related quality of life. Health Policy 16:199–208CrossRef

Nishimura S, Tsuchiya A, Hisashige A et al (1998) The development of the Japanese EuroQol instrument. Iryo To Shakai 8:109–123. https://doi.org/10.4091/iken1991.8.1_109 CrossRef

Ikeda S, Ikegami N, on behalf of the Japanese EuroQol Tariff Project (1999) Health status in Japanese population: results from Japanese EuroQol study. J Health Care Soc 9:83–92CrossRef

Tsuchiya A, Ikeda S, Ikegami N et al (2002) Estimating an EQ-5D population value set: the case of Japan. Health Econ 11:341–353. https://doi.org/10.1002/hec.673 CrossRefPubMed

10.

Herdman M, Gudex C, Lloyd A et al (2011) Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res 20:1727–1736. https://doi.org/10.1007/s11136-011-9903-x CrossRefPubMedPubMedCentral

11.

van Hout B, Janssen MF, Feng YS et al (2012) Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. Value Health 15:708–715. https://doi.org/10.1016/j.jval.2012.02.008 CrossRefPubMed

12.

Ikeda S, Shiroiwa T, Igarashi I et al (2015) Developing a Japanese version of the EQ-5D-5L value set. J Natl Inst Public Health 64:47–55

13.

Shiroiwa T, Fukuda T, Ikeda S et al (2016) Japanese population norms for preference-based measures: EQ-5D-3L, EQ-5D-5L, and SF-6D. Qual Life Res 25:707–719. https://doi.org/10.1007/s11136-015-1108-2 CrossRefPubMed

14.

Feeny D, Furlong W, Boyle M et al (1995) Multi-attribute health status classification systems. Health Utilities Index Pharmacoecon 7:490–502

15.

Brazier J, Usherwood T, Harper R et al (1998) Deriving a preference-based single index from the UK SF-36 Health Survey. J Clin Epidemiol 51:1115–1128CrossRefPubMed

16.

Brauer CA, Rosen AB, Greenberg D et al (2006) Trends in the measurement of health utilities in published cost–utility analyses. Value Health 9:213–218. https://doi.org/10.1111/j.1524-4733.2006.00116.x CrossRefPubMed

17.

Sakamaki H, Ikeda S, Ikegami N et al (2006) Measurement of HRQL using EQ-5D in patients with type 2 diabetes mellitus in Japan. Value Health 9:47–53. https://doi.org/10.1111/j.1524-4733.2006.00080.x CrossRefPubMed

18.

Licitra L, Mesía R, Keilholz U (2016) Individualised quality of life as a measure to guide treatment choices in squamous cell carcinoma of the head and neck. Oral Oncol 52:18–23. https://doi.org/10.1016/j.oraloncology.2015.10.020 CrossRefPubMed

19.

Pfister DG, Spencer S, Brizel DM et al (2015) Head and Neck Cancers, Version 1.2015. J Natl Compr Canc Netw 13:847–855CrossRefPubMed

20.

Cella DF, Tulsky DS, Gray G et al (1993) The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol 11:570–579. https://doi.org/10.1200/JCO.1993.11.3.570 CrossRefPubMed

21.

Fumimoto H, Kobayashi K, Chang CH et al (2001) Cross-cultural validation of an international questionnaire, the General Measure of the Functional Assessment of Cancer Therapy scale (FACT-G), for Japanese. Qual Life Res 10:701–709CrossRefPubMed

22.

D’Antonio LL, Zimmerman GJ, Cella DF et al (1996) Quality of life and functional status measures in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg 122:482–487. https://doi.org/10.1001/archotol.1996.01890170018005 CrossRefPubMed

23.

Rogers SN, Ahad SA, Murphy AP (2007) A structured review and theme analysis of papers published on ‘quality of life’ in head and neck cancer: 2000–2005. Oral Oncol 43:843–868. doi. https://doi.org/10.1016/j.oraloncology.2007.02.006 CrossRefPubMed

24.

Aoki T, Ota Y, Suzuki T et al (2018) Longitudinal changes in the quality of life of oral cancer patients during the perioperative period. Int J Clin Oncol. https://doi.org/10.1007/s10147-018-1322-3. [Epub ahead of print]CrossRefPubMedPubMedCentral

25.

The American Society of Clinical Oncology (1996) Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. J Clin Oncol 14:671–679. https://doi.org/10.1200/JCO.1996.14.2.671 CrossRef

26.

Cherny NI, Sullivan R, Dafni U et al (2015) A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: The European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). Ann Oncol 26:1547–1573. https://doi.org/10.1093/annonc/mdv249 CrossRefPubMed

27.

Feng Y, Parkin D, Devlin NJ (2014) Assessing the performance of the EQ-VAS in the NHS PROMs programme. Qual Life Res 23:977–989. https://doi.org/10.1007/s11136-013-0537-z CrossRefPubMed

28.

McCormack HM, Horne DJ, Sheather S (1988) Clinical applications of visual analog scales: a critical review. Psychol Med 18:1007–1019CrossRefPubMed

29.

Wewers ME, Lowe NK (1990) A critical review of visual analog scales in the measurement of clinical phenomena. Res Nurs Health 13:227–236CrossRefPubMed

Titel: To what extent does the EQ-5D-3L correlate with the FACT-H&N of patients with oral cancer during the perioperative period?
verfasst von: Takayuki Aoki
Yoshihide Ota
Masashi Sasaki
Ken-ichi Aoyama
Takeshi Akiba
Yukari Shirasugi
Mariko Naito
Takeru Shiroiwa
Publikationsdatum: 01.04.2019
Verlag: Springer Singapore
Erschienen in: International Journal of Clinical Oncology / Ausgabe 4/2019
Print ISSN: 1341-9625
Elektronische ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-018-1364-6

Springer Medizin

To what extent does the EQ-5D-3L correlate with the FACT-H&N of patients with oral cancer during the perioperative period?